These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 31182436)

  • 1. Functional Properties of
    Tarlock K; Alonzo TA; Wang YC; Gerbing RB; Ries R; Loken MR; Pardo L; Hylkema T; Joaquin J; Sarukkai L; Raimondi SC; Hirsch B; Sung L; Aplenc R; Bernstein I; Gamis AS; Meshinchi S; Pollard JA
    Clin Cancer Res; 2019 Aug; 25(16):5038-5048. PubMed ID: 31182436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
    Pollard JA; Alonzo TA; Gerbing RB; Ho PA; Zeng R; Ravindranath Y; Dahl G; Lacayo NJ; Becton D; Chang M; Weinstein HJ; Hirsch B; Raimondi SC; Heerema NA; Woods WG; Lange BJ; Hurwitz C; Arceci RJ; Radich JP; Bernstein ID; Heinrich MC; Meshinchi S
    Blood; 2010 Mar; 115(12):2372-9. PubMed ID: 20056794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.
    Chen X; Dou H; Wang X; Huang Y; Lu L; Bin J; Su Y; Zou L; Yu J; Bao L
    Leuk Lymphoma; 2018 Apr; 59(4):829-836. PubMed ID: 28792268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Core binding factor acute myeloid leukaemia and c-KIT mutations.
    Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
    Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia.
    Shafik NF; Ibraheem D; Selim MM; Allam RM; Fathalla LA
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e363-e375. PubMed ID: 34972661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia.
    Tan Y; Liu Z; Wang W; Zhu G; Guo J; Chen X; Zheng C; Xu Z; Chang J; Ren F; Wang H
    Leuk Res; 2018 Jun; 69():89-93. PubMed ID: 29705537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
    Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
    Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
    Allen C; Hills RK; Lamb K; Evans C; Tinsley S; Sellar R; O'Brien M; Yin JL; Burnett AK; Linch DC; Gale RE
    Leukemia; 2013 Sep; 27(9):1891-901. PubMed ID: 23783394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
    Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.
    Jawhar M; Döhner K; Kreil S; Schwaab J; Shoumariyeh K; Meggendorfer M; Span LLF; Fuhrmann S; Naumann N; Horny HP; Sotlar K; Kubuschok B; von Bubnoff N; Spiekermann K; Heuser M; Metzgeroth G; Fabarius A; Klein S; Hofmann WK; Kluin-Nelemans HC; Haferlach T; Döhner H; Cross NCP; Sperr WR; Valent P; Reiter A
    Leukemia; 2019 May; 33(5):1124-1134. PubMed ID: 30635631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia.
    Park SH; Chi HS; Min SK; Park BG; Jang S; Park CJ
    Leuk Res; 2011 Oct; 35(10):1376-83. PubMed ID: 21715005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
    Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
    Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples.
    Shih LY; Liang DC; Huang CF; Chang YT; Lai CL; Lin TH; Yang CP; Hung IJ; Liu HC; Jaing TH; Wang LY; Yeh TC
    Leukemia; 2008 Feb; 22(2):303-7. PubMed ID: 17960171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
    Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
    Qin YZ; Zhu HH; Jiang Q; Jiang H; Zhang LP; Xu LP; Wang Y; Liu YR; Lai YY; Shi HX; Jiang B; Huang XJ
    Leuk Res; 2014 Dec; 38(12):1435-40. PubMed ID: 25449688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of N822K T>A mutation-induced constitutive c-KIT activation in AML cells triggers apoptotic and autophagic pathways leading to death.
    Xu J; Zheng J; Fu X; Wu W; Tao L; Li D; Lin D
    Int J Med Sci; 2019; 16(5):757-765. PubMed ID: 31217744
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).
    Boissel N; Leroy H; Brethon B; Philippe N; de Botton S; Auvrignon A; Raffoux E; Leblanc T; Thomas X; Hermine O; Quesnel B; Baruchel A; Leverger G; Dombret H; Preudhomme C; ;
    Leukemia; 2006 Jun; 20(6):965-70. PubMed ID: 16598313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial.
    Tokumasu M; Murata C; Shimada A; Ohki K; Hayashi Y; Saito AM; Fujimoto J; Horibe K; Nagao M; Itoh H; Kamikubo Y; Nakayama H; Kinoshita A; Tomizawa D; Taga T; Tawa A; Tanaka S; Heike T; Adachi S
    Leukemia; 2015 Dec; 29(12):2438-41. PubMed ID: 25975190
    [No Abstract]   [Full Text] [Related]  

  • 19. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
    Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
    Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative analysis of prognostic factors in Chinese core binding factor leukemia.
    Wang D; Qiao C; Xiao M; Geng Z; Shang Z; He J; Huang M; Yang Y; Zhang N; Liu Y; Li J; Li C; Zhou J
    Biochem Biophys Res Commun; 2012 Nov; 428(3):411-5. PubMed ID: 23107788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.